Pharmacogenetic Markers of Favipiravir Safety in COVID-19 Treatment
The aim of the study was to evaluate the associations of different variants of AOX1 and CYP1A2 genes with safety parameters of favipiravir therapy in patients with COVID-19. Material and Methods. The study included 86 patients hospitalized at Moscow Clinical Hospital No. 15 with a COVID-19 diagnosis...
Saved in:
| Main Authors: | I. I. Temirbulatov, A. V. Kryukov, K. B. Mirzaev, N. P. Denisenko, S. P. Abdullaev, A. V. Petrova, E. P. Tkach, A. V. Shipacheva, D. A. Sychev |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
LLC "Publishing House OKI"
2023-10-01
|
| Series: | Антибиотики и Химиотерапия |
| Subjects: | |
| Online Access: | https://www.antibiotics-chemotherapy.ru/jour/article/view/1049 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Analysis of the Distribution Pattern of Genetic Biomarkers of Safety of Etiotropic Drugs for the Treatment of COVID-19 in Representatives of Ethnic Groups of the Volga Region and the Far East
by: S. N. Tuchkova, et al.
Published: (2025-02-01) -
Prevalence of AOX1 and CYP1A2 gene polymorphisms associated with response to favipiravir therapy in novel coronavirus infection COVID-19 among ethnic groups of the North Caucasus
by: A. T. Leinsoo, et al.
Published: (2025-07-01) -
CYP1A2 genotype and acute effects of caffeine intake on growth hormone and testosterone response to resistance exercise
by: Mohammad Rahman Rahimi, et al.
Published: (2024-07-01) -
A Model for Predicting the Risk of Developing Drug-Induced Liver Injury During Therapy with Favipiravir
by: Yu. V. Shevchuk, et al.
Published: (2025-02-01) -
Study of molecular genetic markers of Gilbert’s syndrome
by: A. A. Ivanova, et al.
Published: (2023-07-01)